What is it about?
In England the cost of liothyronine (T3) drug have had a huge rise (>5000%) in the recent years (2013-2018). We discovered that this caused a drop of prescriptions especially in the most economically deprived areas, where patients lost access to the drug.
Featured Image
Why is it important?
Levothyroxine (LT4) is the principal drug prescribed for hypothyroidism (insufficient levels of thyroid hormones), however in some patients T3 can be also prescribed in combination with LT4, or alone.
Perspectives
Urgent measures are needed to reduce the price of T3 drug in England, and ensure its availability to all patients.
Dr Ilaria IM Muller
Cardiff University
Read the Original
This page is a summary of: Liothyronine cost and prescriptions in England, The Lancet Diabetes & Endocrinology, January 2019, Elsevier,
DOI: 10.1016/s2213-8587(18)30334-6.
You can read the full text:
Contributors
The following have contributed to this page
